Difluprednate is a potent, synthetic, fluorinated corticosteroid for ophthalmic use. It is a difluorinated derivative of prednisolone, designed to have enhanced anti-inflammatory and immunosuppressive activity. It is formulated as an ophthalmic emulsion (0.05% w/v) for topical application to the eye. It is considered a high-potency steroid with a rapid onset of action and is particularly effective in managing post-operative inflammation and endogenous uveitis.
Adult: Instill 1 drop into the conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks post-operatively, then taper to 2 times daily for 1 week. For endogenous uveitis: 1 drop 4 times daily for 14 days, then taper.
Note: Shake the bottle well before use. Tilt head back, pull lower eyelid down to form a pouch. Instill drop without touching the tip to eye or any surface. Close eye gently for 1-2 minutes and apply gentle pressure to the nasolacrimal duct (inner corner of eye) for 2-3 minutes to minimize systemic absorption. Wait at least 5-10 minutes before instilling any other ophthalmic medication.
Difluprednate binds to intracellular glucocorticoid receptors, forming a complex that translocates to the cell nucleus. This complex binds to glucocorticoid response elements (GREs) on DNA, leading to modulation of gene transcription. It upregulates the synthesis of anti-inflammatory proteins (like lipocortin) and downregulates the expression of pro-inflammatory mediators such as prostaglandins, leukotrienes, interleukins (IL-1, IL-2, IL-6), tumor necrosis factor-alpha (TNF-α), and adhesion molecules.
Pregnancy: Category C (US FDA). Animal studies have shown fetal harm. There are no adequate and well-controlled studies in pregnant women. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Avoid prolonged use.
Driving: May cause transient blurred vision immediately after instillation. Patients should not drive or operate machinery until vision clears.
| Other Ophthalmic Corticosteroids | Additive risk of elevated IOP, cataract formation, and infection. | Major |
| Ophthalmic NSAIDs (e.g., Ketorolac, Nepafenac) | May increase risk of corneal adverse events (ulceration, perforation) and delayed healing, especially post-surgery. | Major |
| Systemic Corticosteroids (e.g., Prednisolone) | Additive systemic corticosteroid effects, increasing risk of hypercortisolism and adrenal suppression. | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | Potential to increase systemic levels if significant absorption occurs, though risk is low with topical use. | Theoretical/Minor |
Same composition (Difluprednate (0.05% w/v)), different brands: